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EBSJ Special Section: Systematic Review
Editorial Perspective: Time for Another
Grading System—From PRISMA to
AMSTAR 2
This is an important critical reassessment regarding the pro-
liferative publication trend of “Systematic Reviews” seen
not just in just spine surgery but across all medical special-
ties. With the advent of the “evidence-based medicine” era,
the traditional hierarchy of evidence, which had historically
held prospectively randomized clinical trials at the very
pinnacle of the evidence pyramid, was rearranged in favor
of “well-performed” systematic reviews (SRs) and meta-
analyses (MAs).1 With their overarching and collective
nature, these undertakings can offer a statistically much
more potent literature overview while potentially reducing
bias almost invariably introduced in single studies.2,3 Unde-
niably, SRs and MAs have become essential foundations for
guidelines (ie, National Institute for Health and Care Excel-
lence [NICE] guidelines), they are the “go-to” first look
resource for government agencies and granting bodies alike.
And for future authors, such studies have become a wel-
come primary entry point for a deeper dive towards their
own research projects.
By now, the dramatic proliferation of SRs and MAs has
become a well-reported phenomenon as well as problem in
the scientific publication world.4 As the study by Fontelo
and Liu4 reported, the United States has shown a linear rise
of medical SRs crossing the 1000 publication threshold in
1996 and in 2015 contributing just shy of 10 000 such stud-
ies/year to the peer reviewed literature amounting to a total
of >82 000 publications. In contrast, the People’s Republic
of China (PRC) showed a sudden rise since 2010 and is now
the nation with the second highest number of SR publica-
tions following the United States with 21 000 publications as
of 2015. In the arena of MAs, the PRC now leads the world
in MAs published with almost 4000 per year (15 345 total)
ahead of the United States with just below 2500/year
(16 581 total). Again, the PRC publication profile took a
sudden sharp upward turn after 2009 and since then contin-
ued in a continued logarithmic turn upward.4
There are several well-recognized reasons for the appeal of
SRs and MAs:
 If done well, they hold the potential to provide a “state of
the art” overarching assessment of the body of literature
on a given topic.
 Well-done or unique SRs and MAs promise a ready
bounty of copious citations, especially if published
early-on regarding a novel or hot button topic.
 Frankly speaking, they also offered the convenience of
publishing scientifically even in major scientific jour-
nals from the convenience of a connected desktop work-
station by searching various freely accessible search
engines without having to bother with institutional
review boards or hassling with the increasingly prohibi-
tive cost and rigmarole of de novo clinical research.
Creating a new and well-recognized publication in a
matter of days suddenly became a reality.
The sudden proliferation of SRs and MAs has not unexpect-
edly lead to inconsistent quality standards with journal editors
not necessarily applying existing quality standards to submis-
sions. A telling quote of the authors of this EBSJ study
expressed this deficiency that “most authors (at least in the
spine literature as of 2018) seemed to equate systematic
reviews with systematic literature searching.”
Looking back there was an early recognition of the need to
raise the quality of SRs and MAs. The PRISMA statement was
born from a collaborative effort called QUORUM (QUality Of
Reporting Of Meta-analyses) in 1996.5 The change to the term
PRISMA (Preferred Reporting Items for Systemic reviews and
Meta-Analyses) arose from a wish to include SRs in addition to
a straightforward checklist tool and adopted the definitions
used by the respected Cochrane Collaboration.6
While the intent of the PRISMA group was to provide
authors a checklist tool for their creation of a quality SR or
MA, the AMSTAR (AMeasSurement Tool to Assess systema-
tic Reviews) instrument published in 2007 and its AMSTAR 2
revision published in 2017 were created to create a more user
friendly “critical appraisal tool” of an SR inclusive of nonran-
domized studies (Table 1).7 While both tools share some over-
lap they are meant to be complementary to one another and thus
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are applied sequentially for critical assessment of quality of SR
and MA studies. For instance, Kelly et al8 applied a sequential
analysis of PRISMA and AMSTAR 2 tools to so-called Rapid
Reviews (which are a more recent introduction of a more
“accelerated evidence synthesis”) published throughout 2016
and found poor compliance with both entities with published
reviews showing better compliance with PRISMA guidelines
than with AMSTAR items.
In psychiatry, a larger study assessing AMSTAR 2 in com-
parison with AMSTAR and another rating tool (ROBIS; Risk
Of Bias in Systematic reviews) showed moderate interrater
reliability of AMSTAR 2 and high concordance of this test
with the ROBIS test but not with AMSTAR itself for SRs that
studied psychological and pharmacologic depression treat-
ments but overall found similar validity across all rating tools.9
As the science of rating SRs and MAs is still evolving, the
authors of the present EBSJ study performed a thorough
assessment of spine-related SRs in one publication year
(2018) and applied the AMSTAR 2 criteria to
1. evaluate the quality of compliance of these SR’s with
these new ratings tools and
2. inform the larger spine community about this tool and
its intent.
The authors did not wish to belittle the efforts of the authors
or the 4 historically leading spine journals and their editorial
staff but rather hoped to expand the quality awareness of future
authors and reviewers on the subject matters of SRs and MAs.
The findings, which were (critically low) in 93% of results, will
hopefully lead to an improved adherence to PRISMA standards
at the onset and address the quality standards formulated in the
AMSTAR 2 guidelines. To this end, the evolving field of eva-
luation tools for SRs and MAs introduces a new field on inves-
tigations for a new generation of spine researchers.
Jens R. Chapman
Swedish Medical Center, Seattle, WA, USA
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Table 1. AMSTAR 2 Items.
Item 1: Did the research questions and inclusion criteria for the
review include the components of PICO [population, intervention,
comparison intervention, outcome measures]
Item 2: Did the report of the review contain and explicit statement
that the review methods were established prior to conduct of the
review and did the report justify any significant deviations from the
protocols
Item 3: Did the review authors explain their selection of the study for
inclusion in the review?
Item 4: Did the review strategy authors use a comprehensive
literature search strategy?
Item 5: Did the review authors perform study selection in duplicate?
Item 6: Did the authors perform data extraction in duplicate?
Item 7: Did the authors provide a list of excluded studies and justify
the exclusion?
Item 8: Did the authors describe the included studies in adequate
details?
Item 9: Did the authors use a satisfactory technique for assessing risk
of bias (RoB)?
Item 10: Did the authors report on the sources of funding for the
studies included in the review?
Item 11: If meta-analysis was justified did the review authors use
appropriate methods for statistical combination of results?
Item 12: If meta-analysis: If meta-analysis was performed did the
review authors assess the potential impact of RoB in individual
studies on the results of the meta-analysis or other evidence
synthesis?
Item 13: Did the review authors account for RoB in individual studies
when interpreting/discussing the results of the review?
Item 14: Did the review authors provide a satisfactory explanation for,
and discussion of, any heterogeneity observed in the results of the
review?
Item 15: If they performed quantitative synthesis did the review
authors carry out an adequate investigation of publication bias
(small study bias) and discuss its likely impact on the results of the
review?
Item 16: Did the authors report any potential sources of conflict of
interest, including any funding they received for conducting the
review?
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